Prenetics Global (NASDAQ:PRE) Price Target Raised to $40.00

Prenetics Global (NASDAQ:PRE) had its target price lifted by Benchmark from $30.00 to $40.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

Prenetics Global Stock Performance

Shares of NASDAQ:PRE opened at $18.29 on Wednesday. The firm has a market cap of $308.55 million, a PE ratio of -3.99 and a beta of 0.26. The firm’s fifty day moving average is $18.70 and its 200-day moving average is $18.47. Prenetics Global has a 52 week low of $7.18 and a 52 week high of $23.63.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.07). The business had revenue of $35.95 million during the quarter, compared to the consensus estimate of $36.00 million. Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%. Sell-side analysts forecast that Prenetics Global will post -1.26 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PRE. Jane Street Group LLC acquired a new stake in shares of Prenetics Global during the fourth quarter worth $1,302,000. 683 Capital Management LLC acquired a new position in Prenetics Global in the fourth quarter valued at $1,181,000. Millennium Management LLC acquired a new position in Prenetics Global in the fourth quarter valued at $810,000. Marshall Wace LLP bought a new stake in Prenetics Global during the fourth quarter valued at $788,000. Finally, UBS Group AG boosted its position in Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after acquiring an additional 39,733 shares during the last quarter. Institutional investors and hedge funds own 25.01% of the company’s stock.

Key Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Prenetics said its IM8 business secured $1 billion in non-dilutive financing, which could support growth without issuing new shares and signals strong outside confidence in the subsidiary’s outlook. Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
• Positive Sentiment: Management also highlighted that PRE continues to exceed expectations and is receiving preferential financing, reinforcing the idea that the company may have better operating momentum than the market had assumed. PRE Continues to Exceed Expectations and Receive Preferential Financing
• Positive Sentiment: CEOs comments about using the financing to fuel IM8’s growth suggest the company has a clearer path to scaling a high-growth subsidiary, which can improve investor sentiment around future revenue expansion. Prenetics CEO on securing 1 billion funding to fuel subsidiary IM8’s growth
• Neutral Sentiment: Sidoti and other analysts maintained a generally constructive stance overall, with a consensus recommendation of “Moderate Buy,” but the reports mostly focused on model updates rather than a major new catalyst. Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of Moderate Buy by Analysts
• Negative Sentiment: Sidoti cut earnings estimates for several periods, including 2026-2027 quarters and FY2027, which could weigh on the stock because it implies weaker near-term profitability than previously expected.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.